<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3950">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055494</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457AUS07</org_study_id>
    <nct_id>NCT03055494</nct_id>
  </id_info>
  <brief_title>Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide a comparison of secukinumab to placebo with respect to skin
      inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and
      blood sample analyses.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response of psoriasis skin lesions to treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response in skin histology/K16 expression to treatment (yes, no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response of psoriasis skin lesions to treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Psoriasis Area and Severity Index 90 (yes, no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs, Clinical laboratory variables</measure>
    <time_frame>12 weeks</time_frame>
    <description>Vital signs (blood pressure, weight, waist circumference, body mass index), clinical laboratory variables (glucose, insulin, hs-CRP, HOMA-IR, HbA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of psoriasis skin lesions to treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Response in skin histology/K16 expression to treatment (yes, no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of psoriasis skin lesions to treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Psoriasis Area and Severity Index 90 (yes, no)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients will receive placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients will be switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 followed by monthly dosing up to Week 48</description>
    <arm_group_label>Secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed

          -  Clinical diagnosis of chronic plaque-type psoriasis at least 6 months prior to
             randomization

          -  Moderate to severe plaque psoriasis as defined at baseline by:

               -  ≥10% Body Surface Area (BSA) involvement and

               -  PASI total score of ≥12 and

               -  IGA mod 2011 score of ≥3 (based on a scale of 0-4)

        Exclusion Criteria:

          -  Forms of diagnosed psoriasis other than chronic plaque psoriasis

          -  Medication-induced or medication exacerbated psoriasis

          -  Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A
             or IL-17RA receptors

          -  Ongoing use of prohibited treatments

          -  Pregnant or nursing (lactating) women

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>February 14, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
